167 related articles for article (PubMed ID: 36632223)
1. Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m
Zhao Y; Wen S; Li H; Pan CW; Wei Y; Huang T; Li Z; Yang Y; Fan S; Zhang Y
Theranostics; 2023; 13(2):596-610. PubMed ID: 36632223
[No Abstract] [Full Text] [Related]
2. Functional roles of antisense enhancer RNA for promoting prostate cancer progression.
Pan CW; Wen S; Chen L; Wei Y; Niu Y; Zhao Y
Theranostics; 2021; 11(4):1780-1794. PubMed ID: 33408781
[No Abstract] [Full Text] [Related]
3. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine.
Wen S; Wei Y; Zen C; Xiong W; Niu Y; Zhao Y
Mol Cancer; 2020 Dec; 19(1):171. PubMed ID: 33308223
[TBL] [Abstract][Full Text] [Related]
4. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
6. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
9. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
[TBL] [Abstract][Full Text] [Related]
10. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
[TBL] [Abstract][Full Text] [Related]
11. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.
Bachmann SB; Frommel SC; Camicia R; Winkler HC; Santoro R; Hassa PO
Mol Cancer; 2014 May; 13():125. PubMed ID: 24886089
[TBL] [Abstract][Full Text] [Related]
12. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells.
Josson S; Matsuoka Y; Gururajan M; Nomura T; Huang WC; Yang X; Lin JT; Bridgman R; Chu CY; Johnstone PA; Zayzafoon M; Hu P; Zhau H; Berel D; Rogatko A; Chung LW
PLoS One; 2013; 8(7):e68366. PubMed ID: 23874600
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
[TBL] [Abstract][Full Text] [Related]
15. Establishment of CXCR4-small interfering RNA retrovirus vector driven by human prostate-specific antigen promoter and its biological effects on prostate cancer in vitro and in vivo.
Du YF; Shi Y; Xing YF; Zeng FQ
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1255-64. PubMed ID: 18431597
[TBL] [Abstract][Full Text] [Related]
16. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
[TBL] [Abstract][Full Text] [Related]
17. METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma.
Li HB; Huang G; Tu J; Lv DM; Jin QL; Chen JK; Zou YT; Lee DF; Shen JN; Xie XB
EBioMedicine; 2022 Aug; 82():104142. PubMed ID: 35810559
[TBL] [Abstract][Full Text] [Related]
18. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
19. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
